Redburn Partners Upgrades argenx to Buy
Redburn Partners analyst Charles Pitman upgrades argenx (NASDAQ:ARGX) from Neutral to Buy.
What 4 Analyst Ratings Have To Say About argenx
Over the past 3 months, 4 analysts have published their opinion on argenx (NASDAQ:ARGX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Downgrades argenx to Equal-Weight, Raises Price Target to $351
Morgan Stanley analyst Matthew Harrison downgrades argenx (NASDAQ:ARGX) from Overweight to Equal-Weight and raises the price target from $332 to $351.
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug
ere's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 24)
Expert Ratings for argenx
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $332
Morgan Stanley maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $324 to $332.
Recap: argenx Q2 Earnings
Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 162.86% over the past year to $1.98, which may not compared to the estimate of ($3.63).
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
Analyst Ratings For argenx
Within the last quarter, argenx (NASDAQ:ARGX) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago